ALLEGRIA Therapeutics raises USD 5.1 M

Founded in 2023, ALLEGRIA Therapeutics develops therapies targeting mast cells to treat allergies and associated inflammatory diseases. The USD 5.1 million seed extension will advance its lead programme towards designating a first clinical candidate.

Announced on
Round
Seed
Amount
USD 5.1 M
Location
canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic